InNexus Biotechnology and Affimed Therapeutics have formed a collaboration utilizing Affimed’s antibodies and InNexus’ SuperAntibody antibody enhancement drug development platform. The companies will complete feasibility studies and InNexus will have a right to license one of Affimed’s antibodies, while Affimed will have the right to license SuperAntibody Technology for one antibody. Exercise-of-rights is expected to trigger payments in the form of licensing fees, milestone payments and sales royalty.

“This is a unique product development opportunity for both companies, leveraging Affimed’s antibody generating capability with the potency-enhancing SuperAntibody Technology of InNexus,” said Dr. Charles Morgan, president and chief scientific officer of InNexus. “This provides us with the first candidate, targeting colon cancer, to enter our SuperAntibody Bioequivalent Program.” InNexus’ SuperAntibody Bioequivalent Program, as recently announced, will produce SuperAntibody versions of existing FDA-cleared antibodies.

Dr. Melvyn Little, chief scientific officer of Affimed said, “We are very impressed with the SuperAntibody technology of InNexus and this agreement will allow us to develop superior products based on full length antibodies with high market values. Affimed’s own antibody formats, in particular our proprietary TandAb technology using tetravalent bispecific antibodies to recruit immune effector cells for lysing tumor cells are complimented by this collaboration.”